Insmed (INSM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.06
- Estimate
- -$0.68
- Surprise
- +91.2%
- Revenue (period 2026-06-30)
- $425.5M
- Score at report (before → after)
- 5.4 → 5.9/10
Revenue source: xbrl.
How the report landed
Insmed (INSM) reported a narrower loss than forecast — adjusted EPS of -$0.06 against the -$0.68 estimate (a 91.2% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Buy (Wait) (5.4/10) to Sell at 5.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates INSM Sell at 5.6/10.
2 of the last 4 quarters beat the estimate; this quarter's +91.2% surprise compares with a +14.9% four-quarter average. Next scheduled report: 2027-02-18.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive news sentiment (+0.75)
What argues against it
- Concentration risk — Product: ARIKAYCE and BRINSUPRI
- Concentration risk — Supplier: Lamira device
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $104.44
- Price target
- $174.40
- Stop
- $97.13
- Upside to target
- +67.0%
- Reward-to-risk
- 5.9:1
Risk check: trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
INSM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $23.98B
- P/E (fwd)
- 146.5
- 52-week range
- $90.39–$212.75
- Off 52-week high
- 50.9%
- RSI (14)
- 59
- Volume vs avg
- 1.63×
- Score today
- 5.6/10